A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

Status:
NOT_YET_RECRUITING

Trial end date:
2027-10-25

Target enrollment:

Participant gender:

The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.

PHASE3

Bristol-Myers Squibb

trospium chloride
xanomeline